Scott Hensley

Updated March 24, 2021 at 11:03 PM ET

AstraZeneca's latest data analysis affirms effectiveness of its COVID-19 vaccine and is roughly in line with the results released Monday.

A third COVID-19 vaccine is on the way, and this one requires only one shot for immunization.

The Food and Drug Administration authorized Johnson & Johnson's vaccine for emergency use Saturday, a day after a panel of advisers to the agency voted unanimously (22-0) in its favor.

In a unanimous 22-0, a panel of advisers to the Food and Drug Administration recommended that the COVID-19 vaccine developed by Johnson & Johnson be authorized for emergency use in adults during the pandemic.

The vote in favor of the vaccine, which requires only one shot for protection, was taken to answer this question: Do the benefits of the Johnson & Johnson vaccine outweigh its risks for use in people 18 years of age and older.

The Food and Drug Administration released an analysis of Johnson & Johnson's COVID-19 vaccine Wednesday morning that supports its authorization for emergency use.

On Friday, a panel of advisers to the agency will meet to evaluate the vaccine and make a recommendation about whether it should be given the OK. If the agency goes on to authorize the Johnson & Johnson vaccine, it would be the third, after those made by Pfizer-BioNTech and Moderna, to become available in the U.S.

A global study of nearly 44,000 found that the COVID-19 vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease.

The study was conducted in the U.S., Latin America and South Africa. The vaccine did better at preventing disease in the U.S. – 72% — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%.

The biotech company Novavax says its COVID-19 vaccine is 89% effective at preventing the illness, according to an interim analysis of a large study conducted in the U.K.

The results come from a clinical trial involving more than 15,000 volunteers, of whom more than a quarter were older than 65.

The company says 62 cases of COVID-19 were seen in the study. Fifty-six occurred in the group that got placebo; six were seen in people who received the vaccine.

In a 20-0 vote, with one abstention, a panel of advisers to the Food and Drug Administration recommended that the COVID-19 vaccine being developed by Moderna be authorized for emergency use in adults during the pandemic.

If the agency authorizes the vaccine for emergency use, as is expected, it would become the second to be deployed in the U.S to fight the coronavirus.

The vote in favor of the vaccine was taken to answer the agency's question: Do the benefits of the Moderna vaccine outweigh its risks for use in people age 18 and older?

The Food and Drug Administration released a detailed analysis Tuesday morning of the COVID-19 vaccine from drugmaker Moderna that supports the authorization of the company's vaccine for emergency use.

The FDA's briefing document along with one from Moderna were posted two days before a group of experts will convene to advise the agency on whether to grant the vaccine emergency authorization for use, or EUA, during the pandemic.

Updated at 8:22 p.m. ET

In a 17-4 vote, with one abstention, a panel of advisers to the Food and Drug Administration recommended Thursday that the COVID-19 vaccine being developed by Pfizer and BioNTech be authorized for emergency use during the coronavirus pandemic.

The vote in favor of the vaccine was taken to answer the agency's question: Do the benefits of the Pfizer-BioNTech COVID-19 vaccine outweigh its risks for use in people age 16 and older?

The agency typically follows the advice of its expert advisers.

The Food and Drug Administration released a detailed analysis Tuesday morning of the COVID-19 vaccine from Pfizer and its partner BioNTech ahead of a Thursday meeting of a group of independent experts that will advise the agency on whether to grant the vaccine an emergency use authorization.

Facebook and Twitter took measures to screen against misinformation after President Trump put posts on both sites that falsely claimed COVID-19 is less deadly than the flu in "most populations."

Facebook took down Trump's post, saying that users are not allowed to make false claims about the severity of the pandemic. The social network says the post broke its rules against harmful misinformation.

Do you find yourself getting ticked off more often than you used to?

If the answer is yes, you're not alone.

Some 84% of people surveyed said Americans are angrier today compared with a generation ago, according to the latest NPR-IBM Watson Health poll.

When asked about their own feelings, 42% of those polled said they were angrier in the past year than they had been further back in time.

Anger can have an effect on health.

NPR and Kaiser Health News are undertaking a project to investigate and dissect real-life medical bills.

We expect that examining the bills will shed light on the often surprising prices for health care in the U.S.

Along the way, we're hoping to help people learn how to be more active and successful in managing the costs of their care.